Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2023-06-26 Earnings Release
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 99% confidence The document is titled "MedinCell publie ses résultats financiers annuels consolidés" (MedinCell publishes its consolidated annual financial results) and explicitly covers the fiscal year "avril 2022 - mars 2023". It contains detailed consolidated financial statements (Income Statement, Cash Flow Statement, Balance Sheet) for the 12-month period ending March 31, 2023, and compares them to the previous year. This structure and content strongly indicate a comprehensive annual financial report. Although it is presented as a press release format, the core content is the annual financial data, which aligns best with the Annual Report (10-K) definition, even if it might be a preliminary release of the full 10-K filing. Given the depth of the financial tables and the explicit mention of 'résultats financiers annuels consolidés' covering a full fiscal year, 10-K is the most appropriate classification over a simple Earnings Release (ER) or Interim Report (IR). The document is long enough (26k chars) to not be a simple RPA. FY 2023
2023-06-26 French
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive financial results announcement for MedinCell for the fiscal year ending March 31, 2023. It contains detailed financial statements (Profit and Loss, Cashflow, Balance Sheet), management commentary on business trends, product pipeline updates, and financial strategy. While it functions as an earnings release, the inclusion of full-year financial tables and detailed management analysis of the fiscal year performance aligns it with the definition of an Interim/Quarterly Report (IR) in the context of annual/periodical financial reporting, as it provides substantive financial data and analysis for the period. FY 2023
2023-06-26 English
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is a short announcement dated June 20, 2023, stating that MedinCell will present its 2022-2023 annual results (for the year ending March 31, 2023) via a videoconference on June 26, 2023. It provides links to watch the meeting and details on how to submit questions. Since the document is short (2601 chars) and its primary function is to announce the publication/presentation of the annual results (which would typically be a 10-K or MDA), it fits the definition of a Report Publication Announcement (RPA). It is not the full annual report itself, nor is it a transcript or an earnings release summary.
2023-06-20 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated June 20, 2023, announcing a videoconference scheduled for June 26, 2023, to present the 'résultats annuels 2022-2023' (annual results for the fiscal year ending March 31, 2023). This announcement is about the upcoming release and discussion of annual financial results, which typically accompanies or precedes the full Annual Report (10-K) or the Earnings Release (ER). Since it specifically announces the presentation/discussion of the annual results and provides details for the call, it functions as an announcement related to the earnings/results disclosure. Given the context of presenting *annual* results, it is closely related to the 10-K filing, but the document itself is an announcement of a presentation event. The closest fit among the options for an announcement regarding the release/discussion of financial results is 'Earnings Release' (ER), although it pertains to annual results rather than quarterly ones. However, the document's primary function is to announce the *event* where the results will be presented, which aligns strongly with the purpose of an Earnings Release announcement or a Call Transcript announcement (CT). Since it is announcing the presentation of the results, and not the transcript itself, ER is a strong candidate. If the document were the full financial statement, it would be 10-K. Since it is an announcement of the results presentation event, ER is the most appropriate classification for the initial disclosure event. FY 2023
2023-06-20 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights), dated June 6, 2023, and references Article 223-16 of the AMF General Regulation. It explicitly provides a table showing the total number of shares and voting rights as of May 31. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory filing requirement, often related to major shareholding notifications or capital structure updates, but the most fitting category among the provided definitions for a routine monthly disclosure on share capital and voting rights is related to significant ownership changes or capital structure, which aligns closely with 'Major Shareholding Notification' (MRQ) or a general regulatory filing. Since it is a mandatory monthly disclosure about the total number of shares and voting rights, it is a specific regulatory update. Given the options, 'Major Shareholding Notification' (MRQ) is often used for filings related to changes in the total capital base that might trigger threshold crossings, or it falls under a general regulatory filing. However, the content is purely about the total share count and voting rights, which is a specific regulatory disclosure. Looking at the definitions, 'MRQ' (Major Shareholding Notification) is the closest fit for disclosures related to share capital thresholds, although this is a total count disclosure. If it were purely a general announcement, RNS would apply. Since it is a specific, recurring regulatory disclosure about the capital structure, and MRQ deals with changes in significant ownership, I will classify it as a specific regulatory filing related to capital structure/voting rights. Given the options, and the nature of the disclosure (monthly capital/voting rights), it is a specific regulatory filing. If we strictly follow the definitions, it doesn't perfectly match MRQ (which is about *changes* in significant ownership crossing thresholds), but it is a mandatory disclosure about the capital base. In many contexts, these monthly capital updates are filed under general regulatory announcements. However, since it details the total voting rights, which is crucial for shareholder thresholds, MRQ is a strong candidate. Let's re-evaluate: It is a mandatory monthly disclosure of the total share count and voting rights, required by the AMF. This is a very specific regulatory filing. Since there isn't a dedicated 'Share Capital Disclosure' code, and it relates to the base upon which major shareholdings are calculated, MRQ is the most relevant category dealing with share ownership structure disclosures. If MRQ is too specific, RNS is the fallback. Given the precision required, and the focus on voting rights/capital base, I lean towards MRQ as the most specific fit related to ownership structure reporting, or RNS as the general regulatory filing. I will choose RNS as the most appropriate general regulatory filing for this specific monthly capital structure report that doesn't fit the other specific categories perfectly (like DIV, SHA, POS).
2023-06-06 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a very short announcement (2309 characters) explicitly stating that MedinCell 'will publish its annual results' on a future date (June 26, 2023). It details a postponement of the results publication date and mentions that a videoconference will be held on the same day. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the future release of a report, rather than containing the report itself, should be classified as a Report Publication Announcement (RPA).
2023-06-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.